EFS, where events include disease progression or relapse, second malignancy, or death [ Time Frame: Up to 48 months ] [ Designated as safety issue: No ] Primary analysis will be based 1-sided log rank test comparison of EFS curves between the 2 randomized arms per intention-to-treat principle.
Clinical Trial Information
Trial Contact: Boettger, Sadie; El-Shami, Jessica
Age Group: Pediatric
Phase: Drug: Phase III
Principal Investigator: Vincent F. Giusti, MD
Secondary Protocol No:
Applicable Disease Sites: Classical Hodgkin Lymphoma